#Efgartigimod
Hoppala fast vergessen…
#TeamMyastheniaGravis
August 12, 2026 at 10:12 AM
This efgartigimod Ph3 data for autoimmune myositis is a big deal. For immune-mediated necrotizing myopathy (IMNM), a severe muscle-attacking disease with no approved options, patients saw a statistically significant 15.4-point greater improvement in a key symptom score.
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune M
A global immunology company, argenx, reported positive results from its Phase 3 ALKIVIA study, showing that the drug VYVGART® Hytrulo (efgartigimod) significantly improved symptoms in adults with auto
argenx.com
August 19, 2026 at 2:01 PM
NEW: 53 participants involved in the Vyvgart trial for Long COVID are calling on the government to fund research for the drug after they saw significant improvements that the study didn’t capture.

thesicktimes.org/2025/10/10/v...
Vyvgart brought us back to life, but the Long COVID trial was canceled. We are calling on the NIH and HHS to study the drug. - The Sick Times
We are a group of 53 individuals with Long COVID from across the U.S. In 2023, we joined a Long COVID clinical trial for Vyvgart (efgartigimod), a drug approved by the Food and Drug Administration (FD...
thesicktimes.org
October 10, 2025 at 5:05 PM
1) The graph below gives an overview of treatments targeting autoantibodies in Long Covid and ME/CFS.

Efgartigimod = Vygart
Rovunaptabin = BC007

The authors conclude that "to date, no AAbs have been conclusively proven to be pathogenic in PCS or ME/CFS."
December 27, 2025 at 9:01 AM
Wann endlich eine große #Efgartigimod Studie für #severeME?

Ach ne, #MEcfs ist ja die Krankheit, um die alle einen Bogen machen.
Für die es kein Geld gibt.
Wo die @dgn-ev.bsky.social Sekte Forschung verhindern will.
Dann halt nicht.

#severeMEAwarenessDay

www.doccheck.com/de/detail/ar...
Efgartigimod: Hoffnung für CIDP-Patienten?
Die Therapieoptionen für Patienten mit chronischer inflammatorischer demyelinisierender Polyradikuloneuropathie sind begrenzt. Ist ein Wirkstoff aus der Myasthenie-Behandlung die Lösung?
www.doccheck.com
August 8, 2025 at 2:30 PM
Argenx just issued a press release in which it says that the company will not advance development of #Efgartigimod in #LongCOVID / #PostCOVID - #POTS based on Phase 2 ALPHA data.

www.argenx.com/news/argenx-...
June 17, 2024 at 5:23 AM
Argenx says efgartigimod met main goal in myositis trial reut.rs/4xFh4OV
Argenx says efgartigimod met main goal in myositis trial
Belgian-Dutch immunology company argenx ARGX.BR said its drug efgartigimod met the primary endpoint ​in a late-stage study treating adults ‌with autoimmune myositis, showing significant improvement in disease activity.
reut.rs
August 17, 2026 at 8:10 AM
🧠 How does subcutaneous efgartigimod perform for CIDP in routine clinical practice?

The ADHERE REAL study will track real-world effectiveness, treatment changes, relapses, and health care use in adults with CIDP in the US and Germany 🇺🇸🇩🇪

🔗 www.neurologylive.com/view/adhere-...
#Neurology #CIDP
ADHERE REAL Study to Assess Real-World Effectiveness of Efgartigimod in CIDP | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
A new study will follow adults with chronic inflammatory demyelinating polyradiculoneuropathy who start subcutaneous efgartigimod in routine practice in the US and Germany.
www.neurologylive.com
September 30, 2026 at 1:47 PM
Intravenous efgartigimod (Vyvgart) continued to demonstrate efficacy and safety in patients with generalized myasthenia gravis who did not have detectable AChR antibodies, data from the open-label period of the ADAPT SERON trial showed. https://www.medpagetoday.com/meetingcoverage/aanem/123224
Efgartigimod Shows Sustained Efficacy in Myasthenia Gravis Subtypes
Benefits continued for patients without antibodies to the acetylcholine receptor
www.medpagetoday.com
October 1, 2026 at 6:59 PM
my favorite flavor!
December 17, 2024 at 9:56 PM
So do your magic…
January 1, 2026 at 9:28 AM
Gute Übersicht zum aktuellen Forschungsstand (04/2025) von Autoantikörper-gerichteten Therapien bei #LongCovid & #MECFS

Vergleich aktueller Erkenntnisse zu #Rituximab, #Efgartigimod, #Daratumumab, #Immunadsorption, #BC007 & #IVIG

Die Tabelle im Link bietet eine schnelle Übersicht der Ergebnisse.
Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome
Published in Expert Opinion on Biological Therapy (Vol. 25, No. 5, 2025)
www.tandfonline.com
November 4, 2025 at 9:30 AM
Hui der gute Stoff ist da…
March 10, 2026 at 9:08 AM
LC Phase 2 trials ongoing, planned, or concluded and when results are due (interim if planned):
- RSLV-132 (soon?)
- Temelimab (Q4 2023)
- Ampligen (Q1 2024)
- Efgartigimod (Q2 2024)
- Hope Bio stem cells (Q2 2024)
- BC007 (Q4 2024)
- AER002 mAb (?)
October 6, 2023 at 2:27 AM
Neurology Live: 'ADDRESS-LC Study of Long COVID Initiated'

'Funded by a grant from the Department of Defense, the study assigns patients to either bezisterim or placebo twice daily for 84 days...'

www.neurologylive.com/view/address...
ADDRESS-LC Study of Long COVID Initiated, Phase 4 Trial Testing IVIg Transition to Efgartigimod, Lack of Rebound Effect Seen in Ozanimod
Neurology News Network. for the week ending May 31, 2025. [WATCH TIME: 4 minutes]
www.neurologylive.com
May 31, 2025 at 2:33 PM
The Sick Times: 'Vyvgart brought us back to life, but the Long COVID trial was canceled. We are calling on the NIH and HHS to study the drug.'

By Clare Banaszewski, Nicole Barrick, Mike Bilik, Addie Davis, Mia Delli Gatti, Ellie Hayes, Roman White

thesicktimes.org/2025/10/10/v...
Vyvgart brought us back to life, but the Long COVID trial was canceled. We are calling on the NIH and HHS to study the drug. - The Sick Times
We are a group of 53 individuals with Long COVID from across the U.S. In 2023, we joined a Long COVID clinical trial for Vyvgart (efgartigimod), a drug approved by the Food and Drug Administration (FD...
thesicktimes.org
October 10, 2025 at 7:36 PM
In 2023, Delli Gatti joined a clinical trial testing a drug called efgartigimod in POTS driven by long COVID, like hers. 4/
July 20, 2026 at 3:05 PM
Results on Efgartigimod for Chronic Inflammatory Demyelinating Polyneuropathy Treatment: Richard Lewis, MD www.neurologylive.com/view/results... via @neurology_live #CIDP
Results on Efgartigimod for Chronic Inflammatory Demyelinating Polyneuropathy Treatment: Richard Lew...
The professor of neurology at Cedars-Sinai Medical Center talked about findings from the ADHERE trial assessing efgartigimod, a human IgG1 antibody Fc fragment, as a treatment for patients with chroni...
www.neurologylive.com
November 12, 2023 at 6:28 PM
Tschüss Ravulizumab, Hallo Efgartigimod alfa. Wir haben nächsten Donnerstag ein Date.
#TeamMyastheniaGravis
October 27, 2025 at 12:40 PM
Moin immer wieder Mittwochs…
August 19, 2026 at 5:58 AM
The GoFundMe, which Delli Gatti set up in November, is part of a last-ditch effort to move development of efgartigimod forward after Delli Gatti and other trial participants were left by the wayside. But nothing is a sure bet in long COVID research. 8/
July 20, 2026 at 3:05 PM
💊 Fuenlabrada cierra la compra de Efgartigimod por 1,88 millones y blinda el suministro del medicamento exclusivo 🏥

https://boesinpaja.es/article/fuenlabrada-cierra-la-compra-de-efgartigimod-por-188-millones-y-blinda-el-suministro-del-medicamento-exclusivo-1951880

#Fuenlabrada #Madrid
September 27, 2026 at 11:13 AM
Rozanolixizumab now sits beside efgartigimod and immunoglobulin in myasthenia gravis, but anchored and unanchored adjustments differ in weight. https://www.mattheneus.com/editorial/pubmed-rozanolixizumab-fcrn-anchored-unanchored-population-adjustment-evidence-2026-09-29 #HTA #MAIC #EvidenceSynthesis
September 29, 2026 at 12:02 PM
Want to hear the results of a study comparing eculizumab with efgartigimod for #MyastheniaGravis based on real-world evidence?

Watch our interview with Francesco Saccà:
👉 https://buff.ly/4gH5muR

#Autoimmune #NeuroScience #NeuroTwitter #EAN2024
Real-world comparison of eculizumab and efgartigimod for generalized myasthenia gravis - VJNeurology
Francesco Saccà, MD, PhD, University of Naples Federico II, Naples, Italy, discusses the results of his study comparing eculizumab (a...
buff.ly
January 2, 2025 at 1:00 PM
Na dann wollen wir mal…
March 31, 2026 at 6:42 AM